Revolution Medicines presented updated Phase 1/2 clinical data for daraxonrasib, an oral RAS(ON) inhibitor, in untreated metastatic pancreatic ductal adenocarcinoma (PDAC) at the 2026 AACR Annual Meeting. Both monotherapy and combination therapy with chemotherapy showed manageable safety profiles and encouraging early antitumor activity, with objective response rates of 47% and 58%, respectively. These findings support ongoing Phase 3 trials to further evaluate daraxonrasib's potential to improve outcomes in this hard-to-treat cancer. The drug targets RAS mutations, which are present in over 90% of PDAC cases, addressing a critical unmet need in pancreatic cancer treatment.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
